John Krahne received alarming news from his doctor last December. His brain tumors were stable, but his lung tumors had grown noticeably larger.
The doctor recommended a drug called Alecensa, which sells for more than $159,000 a year. Medicare would charge Krahne a $3,200 copay in December, then another $3,200 in January, as a new year of coverage kicked in.
For the first time since being diagnosed 10 years ago, Krahne, 65, decided to delay filling his prescription, hoping that his cancer wouldn't take advantage of the lapse and wreak further havoc on his body.
With new cancer drugs commonly priced at $100,000 a year or more, Krahne's story is becoming increasingly common. Hundreds of thousands of cancer patients are delaying care, cutting their pills in half or skipping drug treatment entirely, a Kaiser Health News examination shows.
More
DelMarVa's Premier Source for News, Opinion, Analysis, and Human Interest Contact Publisher Joe Albero at alberobutzo@wmconnect.com or 410-430-5349
I am told that insurance companies bartered support for Obama Care in exchange for their control of drug prices until 2020. You also have insurance companies striking deals with large pharmacy chains and conspiring to put locally owned drug stores out of business. Why can you buy a drug in another country (name brand) for $30 and it costs over $200 here? I hope this nonsense isn't overlooked as AHA is repealed and replaced.
ReplyDeleteLOL. Keep wishing. Trump is on the side of the common folks and not big business, I bet he will fix it. NOT!
ReplyDeleteDrug Companys are Criminal!
ReplyDeleteTrump is on his way to fixing that